文献速递神经肿瘤

原发性中枢神经系统肿瘤中的DICER1突变:组织学、突变与预后的新见解

DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
PubMed 文献 · J Neurooncol · 2022-04-06

该回顾性队列研究纳入1995至2020年间治疗的98例携带DICER1突变或DICER1缺失的原发性中枢神经系统肿瘤患者,分析生存结局。发现3/4级胶质瘤最常见(61%),在3/4级胶质瘤中MGMT甲基化、IDH1 R132突变及DexD/H-box解旋酶结构域错义突变与至全因死亡时间延长独立相关。

要点

  • 3/4级胶质瘤是DICER1突变或缺失原发性中枢神经系统肿瘤中最常见的组织学类型(61%)。
  • 3/4级胶质瘤中MGMT甲基化、IDH1 R132突变与至全因死亡时间延长独立相关。
  • DexD/H-box解旋酶结构域错义突变与3/4级胶质瘤患者至全因死亡时间延长独立相关。

核心结论

  • DICER1突变或DICER1缺失见于多种原发性中枢神经系统肿瘤,其中3/4级胶质瘤为最常见组织学类型,且为既往未认识到的类型。
  • 既往研究描述的是RNaseIIIb热点突变,本研究记录了其他DICER1功能结构域的新发突变。
  • 在3/4级胶质瘤队列中,DexD/H-box解旋酶结构域错义突变与生存期延长相关。

研究设计与样本

  • 回顾性队列研究,纳入1995年至2020年间治疗的98例经靶向下一代测序鉴定、携带DICER1突变或14q染色体上DICER1缺失的原发性中枢神经系统肿瘤患者。
  • 采用Kaplan-Meier曲线和log rank检验分析生存,采用Cox比例风险模型进行全因死亡的单变量和多变量分析。

主要发现

  • 队列中最常见的恶性肿瘤为3/4级胶质瘤(61%)、1/2级胶质瘤(17%)和中枢神经系统肉瘤(6%)。
  • 肉瘤和非胶质瘤组织学类型以及双等位基因DICER1突变或缺失的肿瘤在儿童人群中常见。
  • 突变遍布DICER1,包括DexD/H-box解旋酶、DUF283、RNaseIIIa和RNaseIIIb结构域的错义突变。
  • 在3/4级胶质瘤患者中,多变量分析显示MGMT甲基化(风险比[HR] 0.35,95%置信区间[CI] 0.16-0.73,p=0.005)与至全因死亡时间延长独立相关。
  • 在3/4级胶质瘤患者中,多变量分析显示IDH1 R132突变(HR 0.11,95%CI 0.03-0.41,p=0.001)与至全因死亡时间延长独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to characterize clinical outcomes for adult and pediatric patients with primary CNS tumors harboring DICER1 mutations or loss of DICER1. METHODS: We conducted a retrospective cohort study of 98 patients who were treated between 1995 and 2020 for primary CNS tumors containing DICER1 mutations or loss of DICER1 on chromosome 14q, identified by targeted next generation sequencing. Kaplan-Meier plots and log rank tests were used to analyze survival. Cox proportional-hazards model was used for univariate and multivariable analyses for all-cause mortality (ACM). RESULTS: Within our cohort, the most common malignancies were grade 3/4 glioma (61%), grade 1/2 glioma (17%), and CNS sarcoma (6%). Sarcoma and non-glioma histologies, and tumors with biallelic DICER1 mutations or deletions were common in the pediatric population. Mutations occurred throughout DICER1, including missense mutations in the DexD/H-box helicase, DUF283, RNaseIIIa, and RNaseIIIb domains. For patients with grade 3/4 glioma, MGMT methylation (Hazard ratio [HR] 0.35, 95% Confidence Interval [CI] 0.16-0.73, p = 0.005), IDH1 R132 mutation (HR 0.11, 95% CI 0.03-0.41, p = 0.001), and missense mutation in the DexD/H-box helicase domain (HR 0.06, 95% CI 0.01-0.38, p = 0.003) were independently associated with longer time to ACM on multivariable analyses. CONCLUSION: DICER1 mutations or loss of DICER1 occur in diverse primary CNS tumors, including previously unrecognized grade 3/4 gliomas as the most common histology. While prior studies have described RNaseIIIb hotspot mutations, we document novel mutations in additional DICER1 functional domains. Within the grade 3/4 glioma cohort, missense mutation in the DexD/H-box helicase domain was associated with prolonged survival.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Liu KX, Shang HH, Cacciotti C, et al. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022. PMID: 35384518. doi:10.1007/s11060-022-03994-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。